$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032117 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$9.250M	$8.586M	$8.558M
YoY Change	3.07%	0.32%	15.66%
Cost Of Revenue	$4.331M	$4.761M	$4.790M
YoY Change	-12.63%	-0.6%	26.78%
Gross Profit	$4.919M	$3.824M	$3.768M
YoY Change	22.44%	1.49%	4.05%
Gross Profit Margin	53.18%	44.54%	44.03%
Selling, General & Admin	$1.199M	$1.197M	$930.1K
YoY Change	28.49%	28.65%	16.39%
% of Gross Profit	24.38%	31.29%	24.68%
Research & Development	$1.443M	$1.227M	$1.116M
YoY Change	50.88%	9.92%	-2.72%
% of Gross Profit	29.34%	32.09%	29.63%
Depreciation & Amortization	$314.6K	$316.0K	$299.0K
YoY Change	6.09%	5.67%	-10.56%
% of Gross Profit	6.4%	8.26%	7.94%
Operating Expenses	$2.960M	$2.743M	$2.346M
YoY Change	35.39%	16.96%	2.82%
Operating Profit	$1.959M	$1.081M	$1.423M
YoY Change	6.98%	-24.0%	6.14%
Interest Expense	$322.7K	$242.8K	$376.4K
YoY Change	-28.63%	-35.5%	-67.0%
% of Operating Profit	16.47%	22.45%	26.46%
Other Income/Expense, Net	$1.050M	$445.6K	$376.4K
YoY Change	132.29%	18.4%
Pretax Income	$3.009M	$1.527M	$1.799M
YoY Change	31.79%	-15.13%	-27.58%
Income Tax	$39.25K	$11.59K	$4.000K
% Of Pretax Income	1.3%	0.76%	0.22%
Net Earnings	$2.970M	$1.515M	$1.795M
YoY Change	30.07%	-15.59%	-27.67%
Net Earnings / Revenue	32.11%	17.65%	20.97%
Basic Earnings Per Share	$0.00	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	$1.775K
COMMON SHARES
Basic Shares Outstanding	1.014B shares	1.011B shares	1.011B shares
Diluted Shares Outstanding	1.014B shares	1.012B shares	1.011B shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.91M	$18.56M	$4.491M
YoY Change	145.72%	313.19%	2.86%
Cash & Equivalents	$17.91M	$18.56M	$4.896M
Short-Term Investments
Other Short-Term Assets	$1.108M	$219.9K	$173.6K
YoY Change	33.33%	26.66%	-53.2%
Inventory	$8.602M	$7.468M	$6.546M
Prepaid Expenses
Receivables	$5.546M	$4.230M	$4.672M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.16M	$30.47M	$15.88M
YoY Change	89.78%	91.87%	19.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.23M	$10.54M	$7.339M
YoY Change	44.73%	43.68%	2.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$91.74K	$91.74K	$364.6K
YoY Change	-74.84%	-74.84%	168.12%
Other Assets	$2.577M	$2.577M	$405.0K
YoY Change	536.25%	536.26%	0.01%
Total Long-Term Assets	$19.55M	$19.87M	$14.74M
YoY Change	35.1%	34.79%	2.87%
TOTAL ASSETS
Total Short-Term Assets	$33.16M	$30.47M	$15.88M
Total Long-Term Assets	$19.55M	$19.87M	$14.74M
Total Assets	$52.72M	$50.34M	$30.62M
YoY Change	65.01%	64.39%	10.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.472M	$1.724M	$1.790M
YoY Change	14.63%	-3.72%	203.71%
Accrued Expenses	$4.676M	$4.578M	$3.989M
YoY Change	11.87%	14.78%	-15.59%
Deferred Revenue	$13.33K	$13.33K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$471.4K	$502.6K	$511.2K
YoY Change	17.74%	-1.68%	-69.61%
Total Short-Term Liabilities	$6.654M	$6.843M	$6.304M
YoY Change	13.2%	8.56%	-10.09%
LONG-TERM LIABILITIES
Long-Term Debt	$15.49M	$15.53M	$1.473M
YoY Change	980.9%	954.81%	-47.25%
Other Long-Term Liabilities			$2.346M
YoY Change			-26.39%
Total Long-Term Liabilities	$15.89M	$16.31M	$3.818M
YoY Change	384.49%	327.14%	-36.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.654M	$6.843M	$6.304M
Total Long-Term Liabilities	$15.89M	$16.31M	$3.818M
Total Liabilities	$22.54M	$23.15M	$10.12M
YoY Change	146.16%	128.73%	-22.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$135.3M	-$138.2M
YoY Change
Common Stock	$1.014M	$1.014M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change
Treasury Stock Shares	100.0K shares	100.0K shares
Shareholders Equity	$30.17M	$27.19M	$20.50M
YoY Change
Total Liabilities & Shareholders Equity	$52.72M	$50.34M	$30.62M
YoY Change	65.01%	64.39%	10.93%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	$2.970M	$1.515M	$1.795M
YoY Change	30.07%	-15.59%	-27.67%
Depreciation, Depletion And Amortization	$314.6K	$316.0K	$299.0K
YoY Change	6.09%	5.67%	-10.56%
Cash From Operating Activities	-$567.9K	$1.495M	$153.8K
YoY Change	-118.72%	872.44%	-91.91%
INVESTING ACTIVITIES
Capital Expenditures	$710.00	-$5.105M	-$147.4K
YoY Change	-100.87%	3364.37%	82.26%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$710.00	-$5.105M	-$147.4K
YoY Change	-99.13%	3364.37%	90.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-77.37K	2.385M	-266.5K
YoY Change	-49.71%	-995.05%	8.75%
NET CHANGE
Cash From Operating Activities	-567.9K	1.495M	153.8K
Cash From Investing Activities	-710.0	-5.105M	-147.4K
Cash From Financing Activities	-77.37K	2.385M	-266.5K
Net Change In Cash	-646.0K	-1.225M	-260.1K
YoY Change	-123.09%	370.87%	-116.48%
FREE CASH FLOW
Cash From Operating Activities	-$567.9K	$1.495M	$153.8K
Capital Expenditures	$710.00	-$5.105M	-$147.4K
Free Cash Flow	-$568.6K	$6.601M	$301.1K
YoY Change	-118.25%	2091.84%	-84.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss		usd
	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1		usd
	ELTP	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets		usd
CY2022Q3	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2021Q3	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1		usd
	ELTP	Finitelived Intangible Assets Reductions FinitelivedIntangibleAssetsReductions		usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1		usd
CY2022	ELTP	Finitelived Intangible Assets Reductions FinitelivedIntangibleAssetsReductions		usd
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q3	ELTP	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15697
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 LUDLOW AVENUE
	dei	Entity Address City Or Town EntityAddressCityOrTown	NORTHVALE
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
	dei	City Area Code CityAreaCode	201
	dei	Local Phone Number LocalPhoneNumber	750-2646
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ELTP
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1013915081	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18555034	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8535357	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4229538	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3057913	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	7468286	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	6741170	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	219851	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	526949	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	30472709	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	18861389	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13957320	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13348565	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10543933	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5952992	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23850	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1031884	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405164	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405039	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	91738	usd
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	91738	usd
CY2022Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	496902	usd
CY2022Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	496777	usd
CY2022Q3	us-gaap	Assets Assets	50343250	usd
CY2022Q1	us-gaap	Assets Assets	35148898	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1723592	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1430985	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4578470	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4693142	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2022Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	110822	usd
CY2022Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	100822	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	391779	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	253006	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25065	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202953	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6843061	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6694241	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25556	usd
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32226	usd
CY2022Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1021940	usd
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1139848	usd
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	14510462	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	249046	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2163	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	835893	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	748661	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38780	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	16308782	usd
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3232630	usd
CY2022Q3	us-gaap	Liabilities Liabilities	23151843	usd
CY2022Q1	us-gaap	Liabilities Liabilities	9926871	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1011385	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164722951	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164577227	usd
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138238722	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140059744	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27191407	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50343250	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35148898	usd
CY2022Q3	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	7187363	usd
CY2021Q3	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	7221711	usd
	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	13514504	usd
	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	12971747	usd
CY2022Q3	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1398400	usd
CY2021Q3	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1336730	usd
	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	2744167	usd
	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	2643483	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8585763	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8558441	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16258671	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15615230	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	4761329	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	4790292	usd
	us-gaap	Cost Of Revenue CostOfRevenue	8436390	usd
	us-gaap	Cost Of Revenue CostOfRevenue	8253369	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	3824434	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	3768149	usd
	us-gaap	Gross Profit GrossProfit	7822281	usd
	us-gaap	Gross Profit GrossProfit	7361861	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1227269	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1116488	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2182712	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2356275	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1190523	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	925872	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2908627	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1999127	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5973	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4176	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11295	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6987	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	319552	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	299036	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	615846	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	611738	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2743317	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2345572	usd
	us-gaap	Operating Expenses OperatingExpenses	5718480	usd
	us-gaap	Operating Expenses OperatingExpenses	4974127	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1081117	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1422577	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	2103801	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	2387734	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	688319	usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	419433	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	188176	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1033894	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	242753	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	43083	usd
	us-gaap	Interest Expense InterestExpense	459540	usd
	us-gaap	Interest Expense InterestExpense	88976	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	43	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	21	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	172	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	64	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	445609	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	376371	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-271192	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	944982	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1526726	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1798948	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1832609	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3332716	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11587	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11587	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2021Q3	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss	2029	usd
	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss	857379	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1515139	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1796977	usd
	us-gaap	Net Income Loss NetIncomeLoss	1821022	usd
	us-gaap	Net Income Loss NetIncomeLoss	4186095	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012228256	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011281988	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011762632	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1010059593	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1515139	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012228256	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011281988	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011762632	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1010059593	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5322	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25533232	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5974	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60000	usd
CY2022Q3	ELTP	Shares Issued In Payment Of Consulting Expenses SharesIssuedInPaymentOfConsultingExpenses	77062	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27191407	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16151929	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	2389118	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2811	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	157500	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	18701358	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1796977	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4176	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	20502511	usd
	us-gaap	Net Income Loss NetIncomeLoss	1821022	usd
	us-gaap	Net Income Loss NetIncomeLoss	4186095	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	615846	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	611738	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	56272	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	115960	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	188176	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1033894	usd
	ELTP	Accrued Compensation Non Cash AccruedCompensationNonCash	288415	usd
	ELTP	Accrued Compensation Non Cash AccruedCompensationNonCash	428999	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	11296	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6987	usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	602	usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	1143	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1171625	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1175982	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	727116	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1532756	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-307098	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-290338	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13962	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	97724	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6670	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6666	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55104	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-152311	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	115000	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	110000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14550000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-120442	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	937898	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1869244	usd
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	5199696	usd
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	152311	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5199696	usd
	ELTP	Other Loan Payment OtherLoanPayment	153400	usd
	ELTP	Other Loan Payment OtherLoanPayment	309025	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14281600	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-419025	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10019802	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1297908	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3597781	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18960198	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4895689	usd
	us-gaap	Interest Paid Net InterestPaidNet	459540	usd
	us-gaap	Interest Paid Net InterestPaidNet	88976	usd
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	244124	usd
	us-gaap	Stock Issued1 StockIssued1	137067	usd
	us-gaap	Stock Issued1 StockIssued1	157500	usd
	ELTP	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	1042800	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8585763	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8558441	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16258671	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15615230	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	405164	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	405039	usd
	us-gaap	Payments For Rent PaymentsForRent	125754	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1515139	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1796977	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1821022	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4186095	usd
CY2022Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	688319	usd
CY2021Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-418433	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	188176	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-1033894	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2203458	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1378544	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2009198	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3152201	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012228256	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011281988	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011762632	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1010059593	shares
CY2022Q3	ELTP	Long Term Debt Maturities Repayments Of Principals In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalsInNextTwelveMonths	209266	usd
CY2022Q3	ELTP	Long Term Debt Matuities Repayments Of Principal In Year Two LongTermDebtMatuitiesRepaymentsOfPrincipalInYearTwo	327317	usd
CY2022Q3	ELTP	Long Term Debts Maturities Repayments Of Principal In Year Three LongTermDebtsMaturitiesRepaymentsOfPrincipalInYearThree	294157	usd
CY2022Q3	ELTP	Long Term Debt Maturities Repayment Of Principal In Year Four LongTermDebtMaturitiesRepaymentOfPrincipalInYearFour	227306	usd
CY2022Q3	ELTP	Long Term Debt Maturities Repayment Of Principal In Year Five LongTermDebtMaturitiesRepaymentOfPrincipalInYearFive	198040	usd
CY2022Q3	ELTP	Long Term Debt Maturities Repayment Of Principal In Due After Year Five LongTermDebtMaturitiesRepaymentOfPrincipalInDueAfterYearFive	13646155	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012228256	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011281988	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011762632	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1010059593	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	188176	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	748661	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	425072	usd
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	159808	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	95707	usd
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1203204	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	6947507	usd
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5378158	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	7468286	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	6741170	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24501253	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19301557	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13957320	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13348565	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10543933	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5952992	usd
CY2022Q3	us-gaap	Depreciation Depreciation	316007	usd
CY2021Q3	us-gaap	Depreciation Depreciation	295491	usd
	us-gaap	Depreciation Depreciation	608755	usd
	us-gaap	Depreciation Depreciation	604648	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3875000	usd
CY2022Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3625000	usd
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	50000	usd
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2022Q3	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	153333	usd
CY2022Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	153333	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	144000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	usd
CY2022Q3	ELTP	Accrued Director Dues AccruedDirectorDues	45000	usd
CY2022Q1	ELTP	Accrued Director Dues AccruedDirectorDues	90000	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	85143	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	131250	usd
CY2022Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	143000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94744	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	126820	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4578470	usd
CY2022Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6744	usd
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	7367	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4693142	usd
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	115000	usd
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	125000	usd
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	130000	usd
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	140000	usd
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	735000	usd
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	1245000	usd
CY2022Q3	us-gaap	Loans Payable LoansPayable	14902241	usd
CY2022Q1	us-gaap	Loans Payable LoansPayable	502052	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	391779	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	253006	usd
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	14510462	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	249046	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	83686	usd
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	17001	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	261265	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	35598	usd
CY2022Q3	us-gaap	Loans Payable LoansPayable	14902241	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	38889	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2022Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	25556	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	45559	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	32226	usd
	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	These line items represent the unamortized amounts of a $200,000 advance payment received for a TAGI Pharma (“TAGI”) licensing agreement with a fifteen-year term beginning in September 2010 and ending in August 2025
CY2020Q4	ELTP	Operating Lease Renewal Term OperatingLeaseRenewalTerm	The Pompano Office Lease is for approximately 1,275 square feet of office space, with Elite taking occupancy on November 1, 2020. The Pompano Office has a term of three years, ending on October 31, 2023
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	6330	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	62877	usd
	us-gaap	Payments For Rent PaymentsForRent	70908	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	12660	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14770	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27430	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	202	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	27228	usd
CY2022Q3	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice	0.1521
CY2022Q1	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice	0.1521
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y7M6D
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y1M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5650000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1100000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermGranted	P9Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13970
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6750000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4530001	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.16
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P2Y1M6D
CY2022Q3	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.10
CY2022Q1	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.10
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	38357	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.115	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11587	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1075	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
	ELTP	Effective Income Tax Rate Reconciliation Valuation Allowance Tax Rate EffectiveIncomeTaxRateReconciliationValuationAllowanceTaxRate	0.21	pure

Files In Submission

Name	View Source	Status
0001493152-22-032117-index-headers.html	Edgar Link	pending
0001493152-22-032117-index.html	Edgar Link	pending
0001493152-22-032117.txt	Edgar Link	pending
0001493152-22-032117-xbrl.zip	Edgar Link	pending
eltp-20220930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
eltp-20220930_cal.xml	Edgar Link	unprocessable
eltp-20220930_def.xml	Edgar Link	unprocessable
eltp-20220930_pre.xml	Edgar Link	unprocessable
eltp-20220930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2022 Q4 Form 10-Q Financial Statement

#000149315222032117 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2022 Q4 Form 10-Q Financial Statement

#000149315222032117 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp